Search for Clinical Trial Results

Sponsored By

Adult T-cell Leukemia/lymphoma - 89 Studies Found

Status Study
Completed Study Name: High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Condition:
  • T-cell Lymphoma
  • Leukaemia

Date: 2013-09-03
Terminated Study Name: TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
Condition: Chronic Myelogenous Leukemia
Date: 2006-12-22
Interventions:
  • Drug: Imatinib Mesylate (IM) I
Completed Study Name: Ruxolitinib for Adult T-Cell Leukemia
Condition:
  • T Cell Leukemia, Adult
  • Leukemia, Adult T-Cell
  • T Cell Leuke
    Date: 2012-10-20
    Interventions: Drug: Ruxolitinib Ruxolitinib 20 mg orally twice daily for 28 days. Patient may continue to receive trea
Recruiting Study Name: Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Condition:
  • Acute Adult T-Cell Leukemia/Lymphoma
  • Adul
    Date: 2015-12-15
    Interventions:
    • Other: Laboratory Biomarker Analysis

Completed Study Name: Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Condition: Leukemia, Adult T-Cell
Date: 2005-07-07
Interventions: Biological: Denileukin diftitox (Ontak) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d int
Completed Study Name: Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
Condition: Lymphoma
Date: 2002-07-08
Interventions:
  • Biological: filgrastim 5 ug/kg
Completed Study Name: Monoclonal Antibody Therapy in Treating Patients With Leukemia
Condition:
  • Lymphoma
  • Radiation Toxicity

Date: 2001-07-11
Interventions:
  • Drug: pentetic acid calcium
  • Radiation: ytt
Completed Study Name: A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas
Condition:
  • Lymphoma
  • Lymphoma, B-cell
  • Lymphoma, Follicular
  • Date: 2016-04-04
    Interventions: Drug: DS-3201b
Completed Study Name: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition:
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Hepatosplenic T-Cell Lymphoma
  • Other: Laboratory Biomarker Analysis

Terminated Study Name: Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
Condition:
  • Peripheral T-cell Lymphomas
  • Adult T-cell Leukemia
  • Date: 2008-06-21
    Interventions: Drug: Lenalidomide Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28
<<< Previous | Next >>>